Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn about a paper he co-authored with colleagues published in Journal of Neuro-Oncology:
“In this important study, we have shown that in glioblastoma patients, a low dose of bevacizumab (5mg/kg) is as effective as a higher dose (10mg/kg), with less toxicity and less burden on the healthcare system.”
Authors: Giulia Cerretti, Alberto Bosio, Giovanni Librizzi, Giovanna Pintacuda, Mario Caccese, Luca Denaro, Francesco Volpin, Marina Coppola, Sara Lonardi, Giuseppe Lombardi et al.
More posts featuring Giuseppe Lombardi.